<DOC>
	<DOCNO>NCT02055157</DOCNO>
	<brief_summary>This Phase 2 , open-label , sequential cohort dose-escalation study BMN 111 child achondroplasia . The primary objective ass safety tolerability daily BMN 111 administer child achondroplasia .</brief_summary>
	<brief_title>A Phase 2 Study BMN 111 Evaluate Safety , Tolerability , Efficacy Children With Achondroplasia</brief_title>
	<detailed_description />
	<mesh_term>Achondroplasia</mesh_term>
	<mesh_term>Natriuretic Peptide , C-Type</mesh_term>
	<criteria>Parent ( ) guardian ( ) willing able provide write , sign inform consent 5 14 year old study end ACH , document clinical ground , confirm genetic testing At least 6month pretreatment growth assessment Study 111901 study entry , one stand height least 6 month prior screen 111202 Negative pregnancy test Screening Visit female â‰¥ 10 year old . If sexually active , willing use highly effective method contraception participate study Ambulatory , able stand without assistance Willing able perform study procedure physically possible Parents/caregivers willing administer daily injection subject Additional inclusion Criteria Optional , Openlabel Extension Phase : Appropriate write informed consent Hypochondroplasia short stature condition ACH Have follow : Hypothyroidism hyperthyroidism Insulinrequiring diabetes mellitus Autoimmune inflammatory disease Inflammatory bowel disease Autonomic neuropathy Recent acute illness associate volume dehydration completely resolve prior first dose study drug Unstable condition require surgical intervention study Growth plate fuse Have history follow : Renal insufficiency , define creatinine &gt; 2 mg/dl Anemia Baseline systolic BP &lt; 75 mm Hg recurrent symptomatic hypotension recurrent symptomatic hypotension , recurrent symptomatic orthostatic hypotension Cardiac vascular disease , include follow : Cardiac dysfunction ( abnormal echocardiogram [ ECHO ] include leave ventricle [ LV ] mass ) Screening Visit Hypertrophic cardiomyopathy Pulmonary Hypertension Congenital heart disease ongoing cardiac dysfunction Cerebrovascular disease Aortic insufficiency Clinically significant atrial ventricular arrhythmia Have ECG show follow : Right leave atrial enlargement ventricular hypertrophy PR ( period time begin atrial depolarization begin ventricular depolarization ) interval &gt; 200 msec QRS ( The Q , R , S heart wave measure electrocardiogram ) interval &gt; 110 msec Corrected QTcF ( Measure correct time start Q wave end T wave heart 's electrical cycle ) &gt; 450 msec Second thirddegree atrioventricular block Documented Vitamin D deficiency Require investigational agent prior completion study period Have receive another investigational product investigational medical device within 30 day Screening visit Use investigational product investigational medical device treatment ACH short stature Current chronic therapy antihypertensive medication , angiotensinconverting enzyme ( ACE ) inhibitor , angiotensin II receptor blocker , diuretic , betablockers , calciumchannel blocker , cardiac glycoside , systemic anticholinergic agent , medication may impair enhance compensatory tachycardia , diuretic , drug know alter renal tubular function Treatment growth hormone , IGF1 ( Insulinlike growth factor ) , anabolic steroid previous 6 month longterm treatment ( &gt; 3 month ) time Longterm treatment ( &gt; 1 month ) oral corticosteroid Concomitant medication prolongs QT/QTcF interval within 14 day 5 halflives , whichever longer , Screening visit Pregnant breastfeed Screening Visit plan become pregnant ( self partner ) time study Limblengthening bonerelated surgery &lt; 18 month prior study enrollment Had fracture long bone spine within 6 month prior screen ( except fracture digit toe ) AST ( Aspartate Transaminase ) ALT ( Alanine Transaminase ) least 3x upper limit normal ( ULN ) total bilirubin least 2x ULN Evidence severe sleep apnea require surgery new initiation CPAP ( Continuous positive airway pressure ) . History malignancy chemotherapy/radiation currently workup suspected malignancy Known hypersensitivity BMN 111 excipients Have condition circumstance , view Investigator , place subject high risk poor treatment compliance complete study Concurrent disease condition would interfere study participation safety Have abnormal finding baseline clinical hip exam image assessment determine clinically significant determine PI . Have history hip surgery severe hip dysplasia Have history clinically significant hip injury 30 day prior screen . History slip capital femoral epiphysis avascular necrosis femoral head . Are unable lie flat prone position Additional Exclusion Criteria Optional , Openlabel Extension Phase : Use restrict therapy initial 6 month study Permanently discontinue BMN 111 initial 6 month study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Achondroplasia</keyword>
	<keyword>Dwarfism</keyword>
	<keyword>Bone Diseases , Developmental</keyword>
	<keyword>Bone Diseases</keyword>
</DOC>